One Medicine, Many Hands: The End of the UAE's Single-Agent Distribution Model

V-Sentinel Editorial · Healthcare supply chain compliance, GCC

---

On 24 February 2026, the Emirates Drug Establishment ended one of the oldest structures in Gulf pharmaceutical distribution: the single authorised agent. A company marketing a medical product in the UAE can no longer route it through one exclusive local agent. It must appoint more than one.¹ For decades, the regulatory and commercial structure around many products centred on a single authorised agent, concentrating market access and distribution responsibility in one organisation. That is now being dismantled, product by product, under Federal Decree-Law No. 38 of 2024.¹

The coverage that followed read it as a market-access story: exclusivity clauses to reopen, prices competition might pull down, ground for distributors previously locked out.² All real, and all told from the manufacturer's side of the table. The operational question has gone almost unasked: what happens to the supply chain when one product is handled through two or three authorised routes at once? That does not resolve in a contract. It resolves in a warehouse, a temperature log, and a recall. The reform itself is sound. Concentrating a product line behind one agent is a genuine vulnerability, and diversifying it away is prudent. But breaking a concentration does not delete risk. It moves it, from concentration to fragmentation.

What the rule actually does, and the roles it touches

"Authorised agent" is a regulatory role, not a description of who physically holds the product, and the distinction matters. Under Federal Decree-Law No. 38 of 2024, a marketing authorisation holder must appoint at least two importers and one or more distributors, and designate one "main" pharmaceutical establishment to own regulatory affairs, pharmacovigilance and quality across the product's lifecycle. Import and distribution are reserved to licensed medical stores, which can take title to product; a medical warehouse may only store. Exemption is available only by Cabinet decision, a narrow carve-out.² So the reform reaches past agency law into physical custody: more than one structure now sits between a manufacturer and the market.

One distinction has to be drawn carefully, because a knowledgeable reader pushes here first. The mechanism changes how a product is registered and accessed, no longer through a single-agent lens. It does not switch off commercial exclusivity. Pharmaceuticals must be imported through a registered commercial agent, and registration confers statutory exclusivity and an uncapped compensation entitlement on termination, with pharmaceutical disputes producing awards into the tens of millions of dirhams.³ The reform changes the economics of exclusivity; the agency rights remain a separate legal matter it does not resolve on the manufacturer's behalf. That nuance is what "the monopoly is over" flattens. Against a market worth around US$5.0 billion in 2025 and forecast near US$8.0 billion by 2033, roughly 80 per cent of it imported, most products reach patients through exactly the agent-and-establishment layer now being restructured.⁴⁵

The risk didn't disappear, it moved

The single-agent model concentrated the distribution interface: fewer organisations between manufacturer and market, simpler governance and escalation. That simplicity was also the vulnerability the reform set out to fix. The multi-agent model substitutes a different one: multiple cold chains to qualify, several SOP sets that may not match, GDP maturity that is uneven across organisations. The integrity of the system becomes dependent on its weakest point, and the patient at the counter cannot see which route the pack came through.

The sharpest case is the excursion. In one custody chain, ownership is clear. Across several, the investigation depends entirely on quality agreements, escalation routes and CAPA ownership drawn up in advance; the obligation does not vanish into ambiguity, but it stops being automatic and starts being something engineered across organisations. Corridors rarely fail inside the cool room. They fail at the handovers, in the minutes when a product belongs to everyone and no one. The reform has multiplied the interfaces.

Traceability shows the same shape. Tatmeen gives the UAE an unusually strong answer to where is this medicine? More than 280 million traceability transactions were recorded by early 2024.⁶ But multiple agents create parallel records, and a recall is only as fast as the least disciplined data set among them. And more legitimate routes do not raise counterfeit risk by themselves, since the national serialisation backbone remains a real defence, but they add control points that must all stay consistently effective. More gates, each held to the same standard.

GDP compliance is not the same as multi-agent governance

Here is the question the commercial coverage never reaches, and it is the one that matters most. A manufacturer can qualify three distributors individually and still build a fragmented system collectively. Good Distribution Practice answers whether each organisation operates compliantly on its own. It does not answer whether three organisations handling one product operate as one coherent network.

The law anticipates part of this. The designated "main" establishment owns the regulatory spine: registration, pharmacovigilance, quality.² But regulatory coordination is not operating the network. Recall exercises across every agent, excursion reporting reconciled between them, batch-allocation and national-stock visibility, common supplier standards, serialisation data reconciled across parties: these are portfolio-level disciplines. They do not follow automatically from each distributor being compliant, nor from one establishment holding the file.

So the model creates a layer above individual warehouse compliance: cross-agent governance. Aligned quality agreements; one escalation protocol every agent is bound to; rehearsed multi-agent recalls; reconciled data; genuine stock visibility across the whole network rather than three partial views of it. The UAE solved the problem of concentration by building a more distributed system. The next challenge is not whether each distributor is compliant on its own. It is whether the product can be governed coherently across all of them, a design problem rather than a certificate.

Three questions that separate readiness from exposure

For a manufacturer appointing agents, or a distributor bidding to become one, three questions locate the gap:

1. If an excursion hit this product at one agent tomorrow, do your quality agreements already say which agent, which batch, and who owns the corrective action, or would that be worked out after the fact across three sets of records?
2. Could you run a recall across every authorised agent and trust that all their serialisation data reconciles, or is it only as good as the weakest custodian's scanning?
3. Who governs this product across all of its agents, covering standards, escalation, recall and stock visibility, or is each compliant alone while no one owns the network?

Answer all three cleanly and you are ready for the multi-agent market. If you cannot, you are carrying fragmentation risk you have not priced, and it now sits closer to the patient than it used to.

The moat moves from contract toward capability

Under the single-agent model, much of the advantage was the position: hold the registered agency and the market for that product was structurally yours. The reform changes that economics. Regulatory access no longer runs through one agent, even where commercial-agency rights persist as a separate matter.³ What rises as the position weakens is capability. When a manufacturer chooses among several agents, operational quality moves from a marginal differentiator to a central part of selection: mature GDP systems, qualified cold chain, clean serialisation, demonstrable inspection readiness. Coverage, tenders, working capital and pharmacovigilance capacity still weigh, but the operator who invested in quality when it did not strictly have to is about to see that repriced upward, while the one who leaned on its position to cover a thin quality organisation will find the position no longer does that work. It is the same movement now visible across the Gulf's corridor build-out: yesterday's differentiator becomes the entry ticket, and advantage moves up a level.

Security you operate, not security you are granted

The reform changes what pharmaceutical security is. It used to be conferred, and once registered, largely fixed. Now it is operated, earned continuously through the condition of the cold chain, the completeness of the serialisation data, the discipline of the handovers, the readiness of the documentation for an inspector who may arrive without notice, and above all whether a product handled by several agents is governed as one network or left as three.⁷

That is the asymmetry worth keeping. The visible part of the reform, reopened contracts and the new commercial map, will be settled in boardrooms this year, and the trade press will cover it thoroughly. The invisible part, whether a product spread across three custodians stays within specification, stays traceable, and stays governable as a whole, will be settled in warehouses and quality agreements, and almost no one is asking about it yet. The concentration everyone wanted broken is breaking. What it leaves behind is not a simpler supply chain but a more demanding one, in which the risk did not disappear when the monopoly did. It moved to where the medicine actually is, and to the question of who now governs it across every hand it passes through.

---

V-Sentinel works with UAE manufacturers, distributors and 3PLs adapting to the multi-agent distribution model. That means not only GDP readiness and cold-chain qualification for each authorised agent, but the cross-agent governance that holds a product together across all of them: aligned quality agreements, escalation and recall protocols, and serialisation reconciliation. Senior expert review, AI-powered delivery. Our GDP Readiness Assessment shows where an operation stands.

---

Sources

Footnotes

1. Emirates Drug Establishment, mechanism ending single-agent exclusivity for medical products (activated 24 February 2026), reported by the Emirates News Agency (WAM), Emirates Drug Establishment breaks monopoly; corroborated by The National, UAE's drug monopoly rules bring promise of cheaper health care (26 February 2026), Khaleej Times, UAE announces rules to end monopoly of medicines, and Gulf News, UAE announces new mechanism to end monopoly of medicines. The mechanism requires companies marketing a medical product in the UAE to appoint more than one authorised local agent per product, ending the single-agent model, and is implemented under Federal Decree-Law No. 38 of 2024 Governing Medical Products, Pharmacists and Pharmaceutical Establishments. wam.ae / thenationalnews.com / khaleejtimes.com / gulfnews.com. ↩ ↩²

2. Mechanics of the requirement under Federal Decree-Law No. 38 of 2024, per Baker McKenzie, United Arab Emirates: Enacts New Medical Products Law to Boost Innovation in Pharmaceuticals and Medical Devices (Healthcare & Life Sciences analysis): the marketing authorisation holder must appoint at least two importers and one or more distributors, and designate one "main" pharmaceutical establishment among its appointed establishments to handle regulatory affairs, vigilance and quality across the product's lifecycle; importation and distribution are reserved to licensed medical stores (which may take title and carry out import, distribution and re-export), while a medical warehouse is licensed only to store; exemption is available only through a Cabinet decision on the proposal of the EDE president, with further conditions to be set by executive regulations. Commercial framing and the note that implementing guidance remains to be finalised, per Middle East Briefing / Dezan Shira & Associates, UAE Pharmaceutical Distribution Reform (21 May 2026) and OMC Medical (6 May 2026). healthcarelifesciences.bakermckenzie.com / middleeastbriefing.com / omcmedical.com. ↩ ↩² ↩³

3. UAE Federal Law concerning Commercial Agencies and legal commentary thereon: pharmaceuticals are among the categories that must be imported through a registered commercial agent; registration with the Ministry of Economy confers exclusive representation rights and a compensation entitlement on termination or non-renewal that carries no statutory cap, with pharmaceutical-sector disputes producing awards into the tens of millions of dirhams. Per legal analyses including Hogan Lovells, New Era for the UAE's Commercial Agencies Law, and Lexology commercial-agency briefings. The interaction between the medical-products framework and commercial-agency rights is a distinct legal question; readers should take specific legal advice. hoganlovells.com / lexology.com / uaelegislation.gov.ae. ↩ ↩²

4. UAE pharmaceutical market sizing per Grand View Research (revenue ~US$5.0 billion in 2025, forecast ~US$8.0 billion by 2033 at ~6.1% CAGR 2026–2033; biologics and biosimilars the fastest-growing molecule segment), as summarised in Middle East Briefing / Dezan Shira & Associates (21 May 2026). Market figures are analyst estimates and vary by source and methodology. grandviewresearch.com / middleeastbriefing.com. ↩

5. Import-dependence estimate (~80% of GCC pharmaceutical supply imported) per Baker McKenzie, Middle East: Pharmaceutical Supply Chains Under Gulf Geopolitical Pressure (May 2026), and AGBI, Gulf push for pharma factories gains urgency (May 2026); consistent with GCC pharmaceutical market analyses. Figures are directional and vary by source. bakermckenzie.com / agbi.com. ↩

6. Tatmeen (UAE national track-and-trace platform) volumes: more than 280 million traceability transactions and over 67 million scanned parcels recorded as of early 2024, per serialisation industry reporting (CosmoTrace); figures are the latest publicly reported at time of writing and have grown since. See V-Sentinel, The UAE Built an Ocean of Pharmaceutical Supply Chain Data. blog.cosmotrace.com. ↩

7. EDE enforcement posture: the Emirates Drug Establishment reported conducting more than 568 regulatory inspection visits to medical warehouses since the start of 2026, and holds powers to inspect without prior notice, seize non-compliant products, and suspend or cancel licences. Gulf News / Zawya, Emirates Drug Establishment conducts over 568 inspections since start of year (2026). gulfnews.com / zawya.com. ↩